{{header
 | author     = Tom Marino
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2014
 | month      = 05
 | day        = 21
 | notes      = ''{{USBill|113|H.R.|4709}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 2
 | title      = Ensuring Patient Access and Effective Drug Enforcement Act of 2014 ( H.R. 4709; 113th Congress)
 | bill       = 4709
 | billtype   = hr
 | purpose    = To improve enforcement efforts related to prescription drug diversion and abuse, and for other purposes.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|2d Session}}

 
{{Center|H. R. 4709}}

 
{{Center|IN THE HOUSE OF REPRESENTATIVES}}

  
{{Center|May 21, 2014}}

 
{{Center| 
[[w:Tom Marino|Mr. Marino]](for himself,
[[w:Marsha Blackburn|Mrs. Blackburn]],
[[w:Peter Welch|Mr. Welch]], and
[[w:Judy Chu|Ms. Chu]]) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]], and in addition to the Committee on the [[w:United States House Committee on the Judiciary|Judiciary]], for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned}}

  
{{Center|A BILL}}

 To improve enforcement efforts related to prescription drug diversion and abuse, and for other purposes.   

=Section 1. Short title=

This Act may be cited as the“   Ensuring Patient Access and Effective Drug Enforcement Act of 2014   ”. 

=Sec. 2. Registration process under Controlled Substances Act=



==(a) Definitions– ==



===(1) Consistent with the public health and safety– ===

   Section 303 of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/823 21 U.S.C. 823] )is amended by adding at the end the following:

<blockquote> 
:(j) In this section, the phrase“consistent with the public health and safety”means having a substantial relationship to this Act’s purpose of preventing diversion and abuse of controlled substances. . 
</blockquote>


===(2) Imminent danger– ===

   Section 304(d) of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/824 21 U.S.C. 824(d)] )is amended—
:(A) by striking“(d) The Attorney General”and inserting“(d)(1) The Attorney General”; and
:(B) by adding at the end the following:

<blockquote> 
::(2) In this subsection, the term imminent danger means a significant and present risk of death or serious bodily harm that is more likely than not to occur in the absence of an immediate suspension order. . 
</blockquote>


==(b) Opportunity To submit corrective action plan prior to revocation or suspension– ==

   Section 304(c) of the Controlled Substances Act ( [http://www.law.cornell.edu/uscode/text/21/824 21 U.S.C. 824(c)] )is amended—
:(1) by striking“(c) Before”and inserting“(c)(1) Before”; and
:(2) by adding at the end the following:

<blockquote> 
::(2) Before revoking or suspending a registration pursuant to section 303 , the [[w:United States Department of Justice|Attorney General]]shall—
:::(A) provide—
::::(i) notice to the registrant of the grounds for revocation or suspension; and
::::(ii) in the case of any such grounds consisting of a violation of law, a specific citation to such law;
:::(B) give the registrant an opportunity to submit a corrective action plan within a reasonable period of time to demonstrate how the registrant plans to correct the grounds for revocation or suspension; and
:::(C) determine whether—
::::(i) in light of the plan, revocation or suspension proceedings should be discontinued or deferred; or
::::(ii) additional changes need to be made in the corrective action plan. . 
</blockquote>
 

=Sec. 3. Report to Congress on effects of law enforcement activities on patient access to medications=



==(a) In general– ==

Not later than one year after the date of enactment of this Act, the [[w:Department of Health and Human Services|Secretary of Health and Human Services]], acting through the [[w:Food and Drug Administration|Commissioner of Food and Drugs]]and the [[w:Centers for Disease Control and Prevention|Director of the Centers for Disease Control and Prevention]], and in consultation with the [[w:Drug Enforcement Administration|Administrator of the Drug Enforcement Administration]]and the [[w:Office of National Drug Control Policy|Director of National Drug Control Policy]], shall submit a report to the Congress—
:(1) assessing how patient access to medications could be adversely impacted by Federal and State law enforcement activities; and
:(2) identifying how collaboration between agencies and stakeholders can benefit patients and prevent diversion and abuse of controlled substances.

==(b) Consultation– ==

The report under subsection (a) shall incorporate feedback and recommendations from the following:
:(1) Patient groups.
:(2) Pharmacies.
:(3) Manufacturers of drugs.
:(4) Common or contract carriers and warehousemen.
:(5) Hospitals, physicians, and other health care providers.
:(6) State attorneys general.
:(7) Law enforcement officials, including local law enforcement officials.
:(8) Health benefit plans and entities that provide pharmacy benefit management services on behalf of a health benefit plan.
:(9) Wholesale drug distributors.  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
